seen from France
seen from United States
seen from Malaysia
seen from United States
seen from Latvia
seen from Türkiye
seen from United Kingdom
seen from United States
seen from Sweden
seen from Romania
seen from Malaysia
seen from United States
seen from Albania
seen from Czechia
seen from Malaysia
seen from China
seen from United Kingdom
seen from Germany
seen from Germany
seen from Sweden
क्या क्लेयर मजूमदार किरण मजूमदार-शॉ की उत्तराधिकारी हैं? बायोकॉन के संस्थापक ने दिया जवाब
किरण मजूमदार-शॉ ने क्लेयर मजूमदार को अपना उत्तराधिकारी बताने वाले एक ट्वीट का जवाब दिया है। बिकारा थेरेप्यूटिक्स की संस्थापक सीईओ क्लेयर, बायोकॉन के संस्थापक और चेयरपर्सन की भतीजी हैं। वह मजूमदार-शॉ के भाई रवि मजूमदार की बेटी हैं। किरण मजूमदार-शॉ और उनकी भतीजी क्लेयर मजूमदार। (एक्स/@किरणशॉ, लिंक्डइन/क्लेयर मजूमदार) जिस ट्वीट से यह सब शुरू हुआ, उसमें किरण मजूमदार-शॉ के बारे में एक लेख शामिल था,…
Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions
https://img.etimg.com/thumb/msid-127837576,width-1200,height-630,imgsize-5030,overlay-etmarkets/articleshow.jpg The Union Budget’s announcement of the ₹10,000 crore Biopharma SHAKTI programme has been welcomed by industry leaders as a significant step towards strengthening India’s domestic biopharmaceutical manufacturing and innovation ecosystem. Speaking to ET Now, Biocon Biologics CEO and MD…
Kiran Mazumdar-Shaw’s Bold Healthcare Mission – Asrar Qureshi’s Blog Post #1203
Dear Colleagues! This is Asrar Qureshi’s Blog Post #1203 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to [email protected] for publishing your contributions here. Credit: Google Images Preamble This blog post is based on a McKinsey Future of Asia interview of Ms. Kiran Mazumdar-Shaw, the…
Biocon reports 95% YoY decline in net profit, operating revenue up 15%
https://img.etimg.com/thumb/msid-123170776,width-1200,height-630,imgsize-23094,overlay-etmarkets/articleshow.jpg Biocon posted a 95% year-on-year decline in reported net profit in the first quarter ended-June. However, the company claims to have on a like-for-like basis booked a 65% increase in profit after tax, after adjusting for the one-time divestment gains it made in the same quarter a year…
Syngene International reports 11% revenue growth and 59% net profit surge in Q1
https://img.etimg.com/thumb/msid-122864069,width-1200,height-630,imgsize-43168,overlay-etmarkets/articleshow.jpg Syngene International, a subsidiary of Biocon, reported 11% year-on-year increase in its first quarter revenue from operations to Rs 875 crore, while net profit for the period surged 59% to Rs 87 crore. A top company official attributed it to continued conversion of pilot programs…
Biocon Eyes Generic Ozempic and Wegovy Sales in Canada @neosciencehub Biocon Ozempic Wegovy Canada semaglutide
Pyscho x Biocon de Max Steel, pq nomás no encontré yaoi de estosss
bendisionesssss
